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COMMENT Open Access
Prospects for using risk scores in polygenic
medicine
Cathryn M. Lewis1,2* and Evangelos Vassos1
Editorial summary
Genome-wide association studies have made strides
in identifying common variation associated with disease.
The modest effect sizes preclude risk prediction based
on single genetic variants, but polygenic risk scores that
combine thousands of variants show some predictive
ability across a range of complex traits and diseases,
including neuropsychiatric disorders. Here, we consider
the potential for translation to clinical use.
What is the polygenic risk score?
Polygenic risk scores (PRSs) summarise genome-wide
genotype data into a single variable that measures genetic
liability to a disorder or a trait. Technically, the PRS is cal-
culated from genome-wide association study (GWAS)
summary statistics, summing the number of risk alleles
carried by an individual, weighted by the effect size from
the discovery GWAS. The PRS is seductive in its simpli-
city, summarising several million genotyped and imputed
common genetic variants, and it is easily calculated using
standard software [1]. The PRS is widely used in research
studies but does it have potential as a clinical tool for risk
prediction, prognosis or stratification?
Currently, the PRS is most often used to follow up
GWAS, testing the prediction of case–control status or
a continuous trait in an independent study. The disease
or trait tested may be the same as that in the discovery
GWAS or different; for example, testing the hypothesis
that the type 2 diabetes PRS predicts depression case–
control status. Such studies give a measure of predictive
ability, such as the proportion of variation in trait status
that is explained.
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The PRS is often standardised for easy interpretation,
rescaling so that scores have a mean of 0 and a standard
deviation of 1. This allows the conversion of an individ-
ual’s PRS to quantiles; for example, identifying the 10%
of the population with the highest PRS. We expect that
the average PRS in cases will be higher than that in con-
trols (indicating a higher genetic risk for the disorder),
but the difference may be small. Many individuals will
have a PRS value close to the population mean, implying
that the PRS adds little information, and the individual’s
predicted risk will be close to the population life-time
disease risk.
For clinical application, the perspective moves from
comparing PRS values in cases and controls to assessing
where an individual’s PRS lies on the population distri-
bution. For example, individuals with the highest 1 or
5% of PRS values, depending on the estimated risk for
the disease and its severity, might be offered regular
screening, encouraged to participate in lifestyle modifi-
cations or prescribed therapeutic interventions. The po-
tential value of using the PRS in defining screening
algorithms has already been observed in breast cancer,
where the PRS was used to stratify breast cancer risk
and to explore the implications for screening [2]. In the
UK, mammogram screening is initiated at the age of 47,
based on a 10-year risk of breast cancer in the average
woman. Mavaddat et al. [2] showed that women in the
top 5% of PRS risk reach this level of risk at the age of
37, while those with the lowest 20% of PRS will never
reach it. This study suggests that, even with our incom-
plete knowledge of breast cancer genetics, a PRS-based
population cancer screening programme could be de-
fined. However, there are substantial barriers to imple-
mentation. These tests will require extensive training of
medical professionals, access to large-scale genotyping
and interpretation; most importantly, the tests are likely
to be controversial, and would need to overcome nega-
tive public attitudes towards genetic testing [3].
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Application of the PRS to brain disorders
If the PRS is constructed from large GWAS of a neuro-
psychiatric disorder it is significantly associated with dis-
ease status. In schizophrenia, for example, the loci
reaching genome-wide significance explain 3.4% of liabil-
ity to schizophrenia, with this component increasing to
7% if an expanded set of independent single nucleotide
polymorphisms (SNPs), at lower significance thresholds,
is included [4]. In amyotrophic lateral sclerosis, common
variation explains 15% of disease liability, with additional
risk conferred by rare variations [5]. Thus, the PRS can
enhance our understanding of the contribution of vari-
ation that explains disease or trait liability.
These findings from research studies reach stringent
statistical significance levels but the proportion of vari-
ation explained is low and falls far short of the level of
predictive ability required for clinical implementation of
risk prediction algorithms. A more focussed target for
translation may be relevant. For example, schizophrenia
PRSs have a moderating influence in carriers of high-risk
copy number variants (CNVs), with schizophrenia cases
carrying a high-risk CNV having a higher PRS than con-
trol individuals, implying that rare and common risk vari-
ants together confer liability to schizophrenia [6]. A
similar model is seen in autism, where PRSs for both aut-
ism and schizophrenia additively contribute to risk in
cases with a de novo variant [7]. Therefore, the PRS may
be useful in determining the risk conferred by a CNV, and
may be of relevance in clinical genetics settings. A natural
translational target would be to use the PRS in genetic
counselling of individuals carrying a high-risk CNV for
schizophrenia, such as the 22q11 or 16p11 deletion.
The PRS also plays a role in determining prognostic
outcome. First episode psychosis patients can have a
wide range of clinical outcomes, and schizophrenia PRSs
differentiated those cases who developed schizophrenia
from those who did not, explaining 9% of the variance
[8]. This ability to predict the development of schizo-
phrenia, a disorder with a potentially worse outcome
than other psychoses, suggests the clinical potential of
the PRS. Improved prediction of the specific diagnosis
early in the course of an illness could have significant
implications for prognosis and treatment plans.
Although we conceptualise clinical disorders as
aetiologically distinct entities, there are substantial genetic
correlations between traits, which may be a valuable source
of additional information for prediction. The potential util-
ity of multi-trait PRS prediction was recently shown by
Krapohl et al. [9], who assessed trait prediction using both
univariate (single) and multivariate PRS, finding a stronger
prediction with the PRS of multiple traits. This strategy in-
creased the proportion of variance explained in body mass
index (BMI) from 3.8% with BMI PRS only to 5.4% when
PRSs for coronary artery disease, age at menarche and other
traits were included. These traits have phenotypic correl-
ation with BMI and provide additional genetic information
beyond that captured by BMI PRS alone. This lack of speci-
ficity of the PRS is likely to be relevant across disorder areas,
and may increase the attainable predictive values of the
PRS. That is, the PRS may be improved to have further dis-
criminative capability by combining the PRS with factors
that affect a particular trait in a multifactorial way.
Challenges of translating the PRS to clinical care
The PRS makes an attractive target for clinical imple-
mentation. PRSs are easy to calculate and store, remain
constant throughout life, and enable prediction to be ob-
tained long before the usual age of onset or an individual
is designated ‘at risk’ through environmental risk factors
or prodromal symptoms.
However, substantial challenges exist before the PRS can
be used in precision medicine. Polygenic medicine will re-
quire a paradigm shift from rare-disorder genetics—which
uses a bivariate yes/no for the presence or absence of a high-
risk variant—to the concept of genetic liability based on a
continuous score. Education for clinicians and the public will
be necessary to increase understanding and genetic literacy.
Organisations such as Genomics England have developed re-
sources to communicate genomic medicine with rare vari-
ants, but resources for polygenic medicine are lacking.
Clinical applications must be widely applicable, but the
translation of the PRS will be hampered by the lack of
genetic research performed in non-European-ancestry
populations. Risk loci are often relevant across popula-
tions, but allele frequencies and linkage disequilibrium
patterns differ. These properties, combined with the
smaller number of research studies available, mean that
the predictive ability of the PRS in non-European popula-
tions is currently limited [8, 10]. Initiatives to increase the
collection of genetic data from non-European-ancestry
populations are currently underway.
Conclusions
The PRS captures important information about an indi-
vidual’s risk of developing a disease. Although as a single
measure the PRS is unlikely to have sufficient utility, it
may be useful for prediction when combined with envir-
onmental risk factors or with high-risk variants such as
CNVs. Given the low predictive ability thus far and the
largely overlapping PRS distributions in cases and con-
trols, we do not necessarily expect that the PRS will have
universal clinical use. However, it may prove useful in
the extremes of distribution (for example, in the top and
bottom deciles of risk). In a technologically driven health
service that is oriented towards big data, the PRS will
surely have a place in risk prediction, as a prognostic in-
dicator or for therapeutic stratification. Now is the time
to start planning for ‘polygenic medicine’.
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